Eye (Lond). 2026 Jul 9. doi: 10.1038/s41433-026-04713-9. Online ahead of print.
ABSTRACT
BACKGROUND/OBJECTIVES: To compare the subjective treatment burden of intravitreal anti-VEGF therapy (IVT) among patients with neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), and macular oedema secondary to retinal vein occlusion (CME).
SUBJECTS/METHODS: This single-centre, cross-sectional study surveyed 393 patients at the Department of Ophthalmology, Hietzing Hospital, Vienna. All participants had received at least five anti-VEGF intravitreal injections and had been in treatment for at least six months. Data were collected via a structured questionnaire, assessing perceived treatment burden, sociodemographics, and treatment-related experiences. Statistical analysis was performed using SPSS, with nonparametric tests applied due to ordinal data.
RESULTS: Of the 393 participants (nAMD: 305; CME: 55; DME: 33), 64% reported no or only slight burden from treatment frequency or injections. There was no statistically significant difference in overall treatment burden between disease groups (p > 0.4). However, the nature of the burden differed: nAMD patients most often cited fear of progressive vision loss, while CME and DME patients more frequently named the injection itself as the greatest burden. Better patient education significantly correlated with a lower perceived burden (p < 0.001). Nearly half of the patients required assistance with clinic visits.
CONCLUSIONS: Although the overall perceived burden of anti-VEGF treatment was similar across retinal diseases, patients’ specific concerns varied. Addressing these differences through personalised education and communication may help alleviate treatment-related anxiety and improve adherence. These findings highlight the importance of tailoring support strategies to individual patient experiences within long-term intravitreal treatment regimens.
PMID:42426273 | DOI:10.1038/s41433-026-04713-9
